Polymyalgia rheumatica

Last updated

Polymyalgia rheumatica
Polymyalgia rheumatica man.svg
In polymyalgia rheumatica, pain is usually located in the shoulders and hips.
Specialty Rheumatology
Symptoms Shoulder, neck and hip pain [1]
Usual onsetAge greater than 50
Diagnostic method Elevated inflammatory markers, CRP and ESR
Differential diagnosis Myositis, giant cell arteritis
Medication Corticosteroids

Polymyalgia rheumatica (PMR) is a syndrome experienced as pain or stiffness, usually in the neck, shoulders, upper arms, and hips, but which may occur all over the body. The pain can be sudden or can occur gradually over a period. Most people with PMR wake up in the morning with pain in their muscles; however, cases have occurred in which the person has developed the pain during the evenings or has pain and stiffness all day long. [1] [2]

Contents

People who have polymyalgia rheumatica may also have temporal arteritis (giant cell arteritis), an inflammation of blood vessels in the face which can cause blindness if not treated quickly. [3] The pain and stiffness can result in a lowered quality of life, and can lead to depression. [1] It is thought to be brought on by a viral or bacterial illness or trauma of some kind, but genetics play a role as well. [4] Persons of Northern European descent are at greater risk. [4] There is no definitive laboratory test, but C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can be useful.

PMR is usually treated with corticosteroids taken by mouth. [5] Most people need to continue the corticosteroid treatment for two to three years. [6] PMR sometimes goes away on its own in a year or two, but medications and self-care measures (e.g., eating the recommended amount of fruits and vegetables) can improve the rate of recovery. [7]

PMR was first established as a distinct disease in 1966 by a case report [8] on 11 patients at Mount Sinai Hospital in New York City. [9] It takes its name from the Greek word Πολυμυαλγία polymyalgia, which means "pain in many muscles".

Signs and symptoms

A wide range of symptoms can indicate if a person has polymyalgia rheumatica. The classic symptoms include: [10]

About 15% of people who are diagnosed with polymyalgia rheumatica also have temporal arteritis, and about 50% of people with temporal arteritis have polymyalgia rheumatica. Some symptoms of temporal arteritis include headaches, scalp tenderness, jaw or facial soreness, distorted vision, or aching in the limbs caused by decreased blood flow, and fatigue. [2]

Causes

The cause of PMR is not well understood. The pain and stiffness result from the activity of inflammatory cells and proteins that are normally a part of the body's disease-fighting immune system, and the inflammatory activity seems to be concentrated in tissues surrounding the affected joints. [12] During this disorder, the white blood cells in the body attack the lining of the joints, causing inflammation. [13] Inherited factors also play a role in the probability that an individual will develop PMR. Several theories have included viral stimulation of the immune system in genetically susceptible individuals. [14]

Infectious diseases may be a contributing factor. This would be expected with sudden onset of symptoms, for example. In addition, new cases often appear in cycles in the general population, implying a viral connection. Studies are inconclusive, but several somewhat common viruses were identified as possible triggers for PMR. [12] As of 2008, per a pamphlet from the Mayo Clinic the viruses thought to be involved included the adenovirus, which causes respiratory infections; the human parvovirus B19, an infection that affects children; and the human parainfluenza virus. [13] [ better source needed ] Subsequent prospective studies have shown, that there is no link between parvovirus B19 and PM. [15]

Persons having the HLA-DR4 type of human leucocyte antigen appear to have a higher risk of PMR. [16]

Diagnosis

No specific test exists to diagnose polymyalgia rheumatica; many other diseases can cause inflammation and pain in muscles, but a few tests can help narrow down the cause of the pain. Limitation in shoulder motion or swelling of the joints in the wrists or hands, are noted by the doctor. [14] A patient's answers to questions, a general physical exam, and the results of tests can help a doctor determine the cause of pain and stiffness. [17]

One blood test usually performed is the erythrocyte sedimentation rate (ESR) which measures how fast the patient's red blood cells settle in a test tube. The faster the red blood cells settle, the higher the ESR value (measured in mm/hour), which suggests that inflammation may be present. Many conditions can cause an elevated ESR, so this test alone is not proof that a person has polymyalgia rheumatica. [17] [18]

Another test that checks the level of C-reactive protein (CRP) in the blood may also be conducted. CRP is produced by the liver in response to an injury or infection, and people with polymyalgia rheumatica usually have high levels. [17] [18] However, like the ESR, this test is also not very specific.[ citation needed ]

Polymyalgia rheumatica is sometimes associated with temporal arteritis, a condition requiring more aggressive therapy. To test for this additional disorder, a biopsy sample may be taken from the temporal artery. [17]

Treatment

Prednisone is the drug of choice for PMR, [19] and treatment duration is frequently greater than one year. [14] If the patient does not experience dramatic improvement after three days of 10–20 mg oral prednisone per day, the diagnosis should be reconsidered. [20] Sometimes relief of symptoms occurs in only several hours.[ citation needed ]

Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen are ineffective in the initial treatment of PMR, [21] but they may be used in conjunction with the maintenance dose of corticosteroid. [22]

Along with medical treatment, patients are encouraged to exercise and eat healthily, helping to maintain a strong immune system and build strong muscles and bones. [23] A diet of fruits, vegetables, whole grains, and low-fat meat and dairy products, avoiding foods with high levels of refined sugars and salt is recommended. [24] Research in the UK has also suggested that people with polymyalgia rheumatica would benefit from a falls assessment when first diagnosed, and regular treatment reviews. [25] [26]

Epidemiology

No circumstances are certain as to which an individual will get polymyalgia rheumatica, but a few factors show a relationship with the disorder:

See also

Related Research Articles

<span class="mw-page-title-main">Arthritis</span> Type of joint disorder

Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include joint pain and stiffness. Other symptoms may include redness, warmth, swelling, and decreased range of motion of the affected joints. In some types of arthritis, other organs are also affected. Onset can be gradual or sudden.

<span class="mw-page-title-main">Giant cell arteritis</span> Inflammatory disease of large blood vessels

Giant cell arteritis (GCA), also called temporal arteritis, is an inflammatory autoimmune disease of large blood vessels. Symptoms may include headache, pain over the temples, flu-like symptoms, double vision, and difficulty opening the mouth. Complications can include blockage of the artery to the eye with resulting blindness, as well as aortic dissection, and aortic aneurysm. GCA is frequently associated with polymyalgia rheumatica. It can be confirmed by biopsy of the temporal artery in about 90% of people.

Rheumatology is a branch of medicine devoted to the diagnosis and management of disorders whose common feature is inflammation in the bones, muscles, joints, and internal organs. Rheumatology covers more than 100 different complex diseases, collectively known as rheumatic diseases, which includes many forms of arthritis as well as lupus and Sjögren's syndrome. Doctors who have undergone formal training in rheumatology are called rheumatologists.

<span class="mw-page-title-main">Erythrocyte sedimentation rate</span> Physiological quantity

The erythrocyte sedimentation rate is the rate at which red blood cells in anticoagulated whole blood descend in a standardized tube over a period of one hour. It is a common hematology test, and is a non-specific measure of inflammation. To perform the test, anticoagulated blood is traditionally placed in an upright tube, known as a Westergren tube, and the distance which the red blood cells fall is measured and reported in millimetres at the end of one hour.

<span class="mw-page-title-main">Fifth disease</span> Red rash due to infection with parvovirus B19

Fifth disease, also known as erythema infectiosum and slapped cheek syndrome, is a common and contagious disease caused by infection with parvovirus B19. This virus was discovered in 1975 and can cause other diseases besides fifth disease. Fifth disease typically presents as a rash and is most common in children. While parvovirus B19 can affect people of all ages, only two out of ten individuals will present with symptoms.

<span class="mw-page-title-main">Ankylosing spondylitis</span> Type of arthritis of the spine

Ankylosing spondylitis (AS) is a type of arthritis from the disease spectrum of axial spondyloarthritis. It is characterized by long-term inflammation of the joints of the spine, typically where the spine joins the pelvis. With AS, eye and bowel problems—as well as back pain—may occur. Joint mobility in the affected areas sometimes worsens over time. Ankylosing spondylitis is believed to involve a combination of genetic and environmental factors. More than 90% of people affected in the UK have a specific human leukocyte antigen known as the HLA-B27 antigen. The underlying mechanism is believed to be autoimmune or autoinflammatory. Diagnosis is based on symptoms with support from medical imaging and blood tests. AS is a type of seronegative spondyloarthropathy, meaning that tests show no presence of rheumatoid factor (RF) antibodies.

<span class="mw-page-title-main">Parvovirus B19</span> Human virus that infects RBC precursors

Human parvovirus B19, generally referred to as B19 virus(B19V),parvovirus B19 or sometimes erythrovirus B19, is a known human virus in the family Parvoviridae, genus Erythroparvovirus; it measures only 23–26 nm in diameter. Human parvovirus b19 is a below-species classification of Erythroparvovirus primate1. The name is derived from Latin parvum, meaning small, reflecting the fact that B19 ranks among the smallest DNA viruses. B19 virus is most known for causing disease in the pediatric population; however, it can also affect adults. It is the classic cause of the childhood rash called fifth disease or erythema infectiosum, or "slapped face syndrome". The name comes from it being the fifth in a list of historical classifications of common skin rash illnesses in children.

<span class="mw-page-title-main">Vasculitis</span> Medical disorders that destroy blood vessels by inflammation

Vasculitis is a group of disorders that destroy blood vessels by inflammation. Both arteries and veins are affected. Lymphangitis is sometimes considered a type of vasculitis. Vasculitis is primarily caused by leukocyte migration and resultant damage. Although both occur in vasculitis, inflammation of veins (phlebitis) or arteries (arteritis) on their own are separate entities.

<span class="mw-page-title-main">Henoch–Schönlein purpura</span> Vascular inflammatory disease

Henoch–Schönlein purpura (HSP), also known as IgA vasculitis, is a disease of the skin, mucous membranes, and sometimes other organs that most commonly affects children. In the skin, the disease causes palpable purpura, often with joint pain and abdominal pain. With kidney involvement, there may be a loss of small amounts of blood and protein in the urine, but this usually goes unnoticed; in a small proportion of cases, the kidney involvement proceeds to chronic kidney disease. HSP is often preceded by an infection, such as a throat infection.

<span class="mw-page-title-main">Polyarteritis nodosa</span> Systemic necrotizing inflammation of medium-sized muscular arteries

Polyarteritis nodosa (PAN) is a systemic necrotizing inflammation of blood vessels (vasculitis) affecting medium-sized muscular arteries, typically involving the arteries of the kidneys and other internal organs but generally sparing the lungs' circulation. Small aneurysms are strung like the beads of a rosary, therefore making this "rosary sign" an important diagnostic feature of the vasculitis. PAN is sometimes associated with infection by the hepatitis B or hepatitis C virus. The condition may be present in infants.

<span class="mw-page-title-main">Arteritis</span> Medical condition

Arteritis is a vascular disorder characterized by inflammation of the walls of arteries, usually as a result of infection or autoimmune responses. Arteritis, a complex disorder, is still not entirely understood. Arteritis may be distinguished by its different types, based on the organ systems affected by the disease. A complication of arteritis is thrombosis, which can be fatal. Arteritis and phlebitis are forms of vasculitis.

Posterior ischemic optic neuropathy (PION) is a medical condition characterized by damage to the retrobulbar portion of the optic nerve due to inadequate blood flow (ischemia) to the optic nerve. Despite the term posterior, this form of damage to the eye's optic nerve due to poor blood flow also includes cases where the cause of inadequate blood flow to the nerve is anterior, as the condition describes a particular mechanism of visual loss as much as the location of damage in the optic nerve. In contrast, anterior ischemic optic neuropathy (AION) is distinguished from PION by the fact that AION occurs spontaneously and on one side in affected individuals with predisposing anatomic or cardiovascular risk factors.

<span class="mw-page-title-main">Giant cell</span> Mass resulting from the fusion of many cells

A giant cell is a mass formed by the union of several distinct cells, often forming a granuloma.

<span class="mw-page-title-main">Pure red cell aplasia</span> Medical condition

Pure red cell aplasia (PRCA) or erythroblastopenia refers to a type of aplastic anemia affecting the precursors to red blood cells but usually not to white blood cells. In PRCA, the bone marrow ceases to produce red blood cells. There are multiple etiologies that can cause PRCA. The condition has been first described by Paul Kaznelson in 1922.

Arteritic anterior ischemic optic neuropathy is vision loss that occurs in giant cell arteritis. Temporal arteritis is an inflammatory disease of medium-sized blood vessels that happens especially with advancing age. AAION occurs in about 15-20 percent of patients with temporal arteritis. Damage to the blood vessels supplying the optic nerves leads to insufficient blood supply (ischemia) to the nerve and subsequent optic nerve fiber death. Most cases of AAION result in nearly complete vision loss first to one eye. If the temporal arteritis is left untreated, the affected eye will likely suffer vision loss as well within 1–2 weeks. Arteritic AION (AAION) falls under the general category of anterior ischemic optic neuropathy (AION), which also includes non-arteritic AION (NAION). AAION is considered an eye emergency, immediate treatment is essential to rescue remaining vision.

<span class="mw-page-title-main">Neuromuscular disease</span> Medical condition

A neuromuscular disease is any disease affecting the peripheral nervous system (PNS), the neuromuscular junctions, or skeletal muscles, all of which are components of the motor unit. Damage to any of these structures can cause muscle atrophy and weakness. Issues with sensation can also occur.

Aortitis is the inflammation of the aortic wall. The disorder is potentially life-threatening and rare. It is reported that there are only 1–3 new cases of aortitis per year per million people in the United States and Europe. Aortitis is most common in people 10 to 40 years of age.

Cerebral vasculitis is vasculitis involving the brain and occasionally the spinal cord. It affects all of the vessels: very small blood vessels (capillaries), medium-size blood vessels, or large blood vessels. If blood flow in a vessel with vasculitis is reduced or stopped, the parts of the body that receive blood from that vessel begins to die. It may produce a wide range of neurological symptoms, such as headache, skin rashes, feeling very tired, joint pains, difficulty moving or coordinating part of the body, changes in sensation, and alterations in perception, thought or behavior, as well as the phenomena of a mass lesion in the brain leading to coma and herniation. Some of its signs and symptoms may resemble multiple sclerosis. 10% have associated bleeding in the brain.

<span class="mw-page-title-main">Systemic vasculitis</span> Medical condition

Necrotizing vasculitis, also called systemic necrotizing vasculitis, is a general term for the inflammation of veins and arteries that develops into necrosis and narrows the vessels.

<span class="mw-page-title-main">Acute visual loss</span> Loss of visual acuity associated with illness or aging

Acute visual loss is a rapid loss of the ability to see. It is caused by many ocular conditions like retinal detachment, glaucoma, macular degeneration, and giant cell arteritis, etc.

References

  1. 1 2 3 "Polymyalgia Rheumatica". National Institute of Arthritis and Musculoskeletal and Skin Diseases. April 11, 2017. Retrieved February 10, 2021.
  2. 1 2 3 4 5 Gelfand JL (November 18, 2007). "Polymyalgia Rheumatica and Temporal Arteritis". WebMD . Retrieved June 10, 2008.
  3. ↑ Schmidt J, Warrington KJ (August 1, 2011). "Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management". Drugs & Aging. 28 (8): 651–66. doi:10.2165/11592500-000000000-00000. PMID   21812500. S2CID   44787949.
  4. 1 2 Cimmino MA (1997). "Genetic and environmental factors in polymyalgia rheumatica". Annals of the Rheumatic Diseases. 56 (10): 576–577. doi:10.1136/ard.56.10.576. PMC   1752263 . PMID   9389216.
  5. ↑ Dejaco C, Singh YP (October 2015). "2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative". Annals of the Rheumatic Diseases. 74 (10): 1799–807. doi: 10.1136/annrheumdis-2015-207492 . hdl: 2445/115060 . PMID   26359488.
  6. ↑ "Polymyalgia Rheumatica treatments and drugs". MayoClinic. December 4, 2010. Retrieved January 19, 2012.
  7. ↑ "Polymyalgia Rheumatica definition". MayoClinic. May 17, 2008. Archived from the original on June 23, 2008. Retrieved January 19, 2012.
  8. ↑ Davison S, Spiera H, Plotz CM (February 1966). "Polymyalgia rheumatica". Arthritis and Rheumatism. 9 (1): 18–23. doi:10.1002/art.1780090103. PMID   4952416.
  9. ↑ Plotz, Charles; Docken, William (May 2013). "Letters: More on the History of Polymyalgia Rheumatica and Giant Cell Arteritis". The Rheumatologist. ACR/ARHP. Archived from the original on February 12, 2015. Retrieved June 1, 2014.
  10. ↑ "Polymyalgia rheumatica". NHS. October 20, 2017. Retrieved July 23, 2021.
  11. ↑ "Polymyalgia Rheumatica symptoms". MayoClinic. December 4, 2010. Retrieved January 19, 2012.
  12. 1 2 "Polymyalgia Rheumatica causes". MayoClinic. December 4, 2010. Retrieved January 19, 2012.
  13. 1 2 "Polymyalgia Rheumatica causes". MayoClinic. May 17, 2008. Archived from the original on June 23, 2008. Retrieved January 19, 2012.
  14. 1 2 3 Shiel Jr WC (March 13, 2008). "Polymyalgia Rheumatica (PMR) & Giant Cell Arteritis (Temporal Arteritis)". MedicineNet. Retrieved June 10, 2008.
  15. ↑ Peris, Pilar (December 2003). "Polymyalgia rheumatica is not seasonal in pattern and is unrelated to parvovirus b19 infection". The Journal of Rheumatology. 30 (12): 2624–2626. ISSN   0315-162X. PMID   14719204.
  16. ↑ Page 255 in: Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to Medicine (Step-Up Series) . Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN   978-0-7817-7153-5.
  17. 1 2 3 4 "Polymyalgia Rheumatica tests and diagnosis". MayoClinic. December 4, 2010. Retrieved January 19, 2012.
  18. 1 2 "Polymyalgia Rheumatica tests and diagnosis". MayoClinic. May 17, 2008. Archived from the original on June 23, 2008. Retrieved January 19, 2012.
  19. ↑ Hernández-Rodríguez J, Cid MC, López-Soto A, Espigol-Frigolé G, Bosch X (November 2009). "Treatment of polymyalgia rheumatica: a systematic review". Archives of Internal Medicine. 169 (20): 1839–50. doi: 10.1001/archinternmed.2009.352 . PMID   19901135.
  20. ↑ McPhee SJ, Papadakis MA (2010). Current Medical Diagnosis and Treatment . p.  767. ISBN   978-0071624442.
  21. 1 2 Docken WP (August 2009). "Polymyalgia rheumatica". American College of Rheumatology. Retrieved January 20, 2012.
  22. ↑ "Polymyalgia rheumatica". MDGuidelines. Retrieved January 20, 2012.
  23. ↑ "Polymyalgia Rheumatica lifestyle and home remedies". MayoClinic. May 17, 2008. Archived from the original on June 23, 2008. Retrieved January 19, 2012.
  24. ↑ "Polymyalgia Rheumatica lifestyle and home remedies". MayoClinic. December 4, 2010. Retrieved January 19, 2012.
  25. ↑ "Polymyalgia rheumatica: treatment reviews are needed". NIHR Evidence. June 21, 2022. doi:10.3310/nihrevidence_51304. S2CID   251774691 . Retrieved August 5, 2022.
  26. ↑ Singh Sokal, Balamrit; Hilder, Samantha L.; Paskins, Zoe; Mallen, Christian D; Muller, Sara (2021). "Fragility fractures and prescriptions of medications for osteoporosis in patients with polymyalgia rheumatica: results from the PMR Cohort Study". Rheumatology Advances in Practice. 5 (3): rkab094. doi:10.1093/rap/rkab094. PMC   8712242 . PMID   34988356.
  27. 1 2 3 "Polymyalgia Rheumatica risk factors". MayoClinic. December 4, 2010. Retrieved January 19, 2012.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.